{"id":"W2618292946","doi":"10.1038/leu.2017.159","title":"A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Azacitidine; Panobinostat; Chronic myelomonocytic leukemia; Neutropenia; Myelodysplastic syndromes; International Prognostic Scoring System; Regimen; Adverse effect; Gastroenterology; Phases of clinical research; Oncology; Bone marrow; Clinical trial; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002072336,0.001853584,0.003050711,0.0005256154,0.0007069326,0.001070951,0.0009686936,0.001477469,0.004894933],"category_scores_gemma":[0.0010751,0.0007961258,0.002135502,0.0006034117,0.00116876,0.001097573,0.0005070543,0.003506388,0.0009934073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001157827,"about_ca_system_score_gemma":0.00230735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002735727,"about_ca_topic_score_gemma":0.006940962,"domain_scores_codex":[0.9993123,0.0003433028,0.00003549238,0.0001379266,0.0000487285,0.0001222164],"domain_scores_gemma":[0.9992442,0.0001121279,0.0001092479,0.00006473292,0.00005331156,0.0004164041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8987919,0.03200843,0.004971501,0.0005779957,0.002038104,0.0001271603,0.0001984113,0.0009232201,0.01781481,0.0001739448,0.002728696,0.03964587],"study_design_scores_gemma":[0.8031659,0.1838538,0.008431727,0.00003011521,0.0009997623,0.0001079381,0.00005723448,0.0002818037,0.001072165,0.0001188501,0.00185823,0.0000225307],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888477,0.003133974,0.0004890878,0.0009605949,0.0002346864,0.002650041,0.002168924,0.00007710985,0.00143791],"genre_scores_gemma":[0.9750582,0.004756216,0.003552159,0.002289161,0.0004770918,0.004405319,0.006073026,0.00006427627,0.003324607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004894933,"threshold_uncertainty_score":0.01637518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02869366442021905,"score_gpt":0.334618221240216,"score_spread":0.305924556819997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}